COMUNICATO STAMPA - CONTENUTO PROMOZIONALE
Financing supports the approval of U.S. Investigational Device Exemption (IDE), coronary clinical advancement, and expansion into below-the-knee peripheral (BTK) applications.
SANTA CLARA, Calif., June 2, 2026 /PRNewswire/ -- Advanced NanoTherapies, Inc. (ANT), a clinical-stage